Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miki Horiguchi

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Statistics in Medicine|January 6, 2023
Ratio and difference of average hazard with survival weight: New measures to quantify survival benefit of new therapyHajime Uno, Miki Horiguchi
JCO Precision Oncology|July 22, 2024
Biomarkers in Oncology: Complexities in Biomarker-Driven Studies and Statistical AnalysisHajime Uno, Miki Horiguchi
Statistics in Medicine|May 21, 2020
On permutation tests for comparing restricted mean survival time with small sample from randomized trialsMiki Horiguchi, Hajime Uno
JCO Precision Oncology|May 23, 2024
Suggestions on Using Machine Learning Models and Cautions for Analyzing Censored Time-To-Event OutcomesYushu Shi, Miki Horiguchi, Ying Lu
Statistics in Medicine|January 19, 2023
On assessing survival benefit of immunotherapy using long-term restricted mean survival timeMiki Horiguchi, Lu Tian, Hajime Uno
Clinical Trials (London, England)|September 16, 2020
Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncologyMiki Horiguchi, Michael J Hassett, Hajime Uno
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate CancerMiki Horiguchi, Hajime Uno, Lee-Jen Wei
The Oncologist|February 12, 2020
Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event OutcomesHajime Uno, Miki Horiguchi, Michael J Hassett
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2018
Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued TreatmentMiki Horiguchi, Hajime Uno, Lee-Jen Wei
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2018
Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall SurvivalRyan Sun, Miki Horiguchi, Lee-Jen Wei
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Statistics in Medicine|January 6, 2023
Ratio and difference of average hazard with survival weight: New measures to quantify survival benefit of new therapyHajime Uno, Miki Horiguchi
JCO Precision Oncology|July 22, 2024
Biomarkers in Oncology: Complexities in Biomarker-Driven Studies and Statistical AnalysisHajime Uno, Miki Horiguchi
Statistics in Medicine|May 21, 2020
On permutation tests for comparing restricted mean survival time with small sample from randomized trialsMiki Horiguchi, Hajime Uno
JCO Precision Oncology|May 23, 2024
Suggestions on Using Machine Learning Models and Cautions for Analyzing Censored Time-To-Event OutcomesYushu Shi, Miki Horiguchi, Ying Lu
Statistics in Medicine|January 19, 2023
On assessing survival benefit of immunotherapy using long-term restricted mean survival timeMiki Horiguchi, Lu Tian, Hajime Uno
Clinical Trials (London, England)|September 16, 2020
Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncologyMiki Horiguchi, Michael J Hassett, Hajime Uno
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate CancerMiki Horiguchi, Hajime Uno, Lee-Jen Wei
The Oncologist|February 12, 2020
Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event OutcomesHajime Uno, Miki Horiguchi, Michael J Hassett
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2018
Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued TreatmentMiki Horiguchi, Hajime Uno, Lee-Jen Wei
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2018
Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall SurvivalRyan Sun, Miki Horiguchi, Lee-Jen Wei
Pageof 4